Abstract

Hexokinase 2 (HK2), which catalyzes the first committed step in glucose metabolism, is induced in cancer cells. HK2’s role in tumorigenesis has been attributed to its glucose kinase activity. Here, we describe a kinase independent HK2 activity, which contributes to metastasis. HK2 binds and sequesters glycogen synthase kinase 3 (GSK3) and acts as a scaffold forming a ternary complex with the regulatory subunit of protein kinase A (PRKAR1a) and GSK3β to facilitate GSK3β phosphorylation and inhibition by PKA. Thus, HK2 functions as an A-kinase anchoring protein (AKAP). Phosphorylation by GSK3β targets proteins for degradation. Consistently, HK2 increases the level and stability of GSK3 targets, MCL1, NRF2, and particularly SNAIL. In addition to GSK3 inhibition, HK2 kinase activity mediates SNAIL glycosylation, which prohibits its phosphorylation by GSK3. Finally, in mouse models of breast cancer metastasis, HK2 deficiency decreases SNAIL protein levels and inhibits SNAIL-mediated epithelial mesenchymal transition and metastasis.

Hexokinase 2 expression is markedly induced in cancer cells and contributes to cancer cell metabolism. Here, the authors show that hexokinase 2 can contribute to the metastatic spread of cancer cells independently of its glycolytic function via inhibiting the activity of GSK3β, which in turn elevates the protein levels of the EMT transcription factor SNAIL.

Details

Title
A non-catalytic scaffolding activity of hexokinase 2 contributes to EMT and metastasis
Author
Blaha, Catherine S 1 ; Gopalakrishnan, Ramakrishnan 1 ; Sang-Min, Jeon 2   VIAFID ORCID Logo  ; Nogueira Veronique 1   VIAFID ORCID Logo  ; Rho Hyunsoo 1 ; Kang Soeun 1   VIAFID ORCID Logo  ; Bhaskar Prashanth 1 ; Terry, Alexander R 1   VIAFID ORCID Logo  ; Aissa, Alexandre F 1   VIAFID ORCID Logo  ; Frolov, Maxim V 1   VIAFID ORCID Logo  ; Patra, Krushna C 3   VIAFID ORCID Logo  ; Brooks, Robey R 4 ; Hay Nissim 5   VIAFID ORCID Logo 

 University of Illinois at Chicago, Department of Biochemistry and Molecular Genetics, College of Medicine, Chicago, USA (GRID:grid.185648.6) (ISNI:0000 0001 2175 0319) 
 Ajou University Yeongtong-gu, College of Pharmacy, Suwon-si, Korea (GRID:grid.251916.8) (ISNI:0000 0004 0532 3933) 
 University of Illinois at Chicago, Department of Biochemistry and Molecular Genetics, College of Medicine, Chicago, USA (GRID:grid.185648.6) (ISNI:0000 0001 2175 0319); University of Cincinnati, Department of Cancer Biology, Cincinnati, USA (GRID:grid.24827.3b) (ISNI:0000 0001 2179 9593) 
 Veterans Affairs Medical Center, White River Junction, Hartford, USA (GRID:grid.413726.5) (ISNI:0000 0004 0420 6436); Geisel School of Medicine at Dartmouth, Hanover, USA (GRID:grid.254880.3) (ISNI:0000 0001 2179 2404) 
 University of Illinois at Chicago, Department of Biochemistry and Molecular Genetics, College of Medicine, Chicago, USA (GRID:grid.185648.6) (ISNI:0000 0001 2175 0319); Jesse Brown VA Medical Center, Research & Development Section, Chicago, USA (GRID:grid.280892.9) (ISNI:0000 0004 0419 4711) 
Publication year
2022
Publication date
2022
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2629161087
Copyright
© This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.